Business Context and Reporting Period
This Form 8-K is a current report filed by Mast Therapeutics, Inc. (the "Company") on January 23, 2017, covering events occurring between January 17 and January 21, 2017. The filing details compensation arrangements and amendments to lock-up agreements in connection with a proposed merger between Mast Therapeutics, Inc. and Savara Inc. (the "Merger").
Key Financial Metrics and Compensation
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. Instead, it discloses specific compensation awards contingent upon the consummation of the Merger:
- 2017 Retention/Performance Bonuses: Approved for Named Executive Officers (NEOs), payable 50% in cash and 50% in Restricted Stock Units (RSUs).
- Additional RSU Grants: Approved to incentivize employees and officers, contingent on the cancellation of existing stock options.
- Stock Option Cancellations: Approximately 16.4 million shares subject to outstanding stock options are expected to be cancelled upon the Merger, as exercise prices are significantly above the current market price.
| Executive Officer | Cash Award (US$) | Retention RSUs (#) | Additional RSUs (#) |
|---|---|---|---|
| Brian Culley, CEO | 53,575 | 382,679 | 1,985,515 |
| Edwin Parsley, CMO | 31,900 | 227,859 | 666,713 |
| Brandi Roberts, CFO | 27,300 | 195,000 | 694,926 |
Note: The filing text does not provide a clear value for the total aggregate cash or equity cost to the Company beyond the specific NEO awards listed.
Material Changes and Agreements
- Lock-Up Amendment: On January 21, 2017, officers and directors entered into Amendment No. 1 to the Lock-Up Agreement. This amendment allows the sale of shares acquired from RSU settlement prior to the lock-up expiration solely to fund tax withholding obligations.
- Compensation Structure: No increases to base salaries or payments under the 2016 Executive Incentive Plan were made. All new awards are contingent on the Merger closing and continued service.
- Share Count Impact: If all approved RSUs vest, approximately 5.1 million shares will be issuable. Concurrently, the cancellation of ~16.4 million option shares is expected to benefit existing stockholders by reducing the share count used to calculate the Exchange Ratio.
Outlook, Risks, and Contingencies
- Merger Contingency: All cash awards and RSU vesting are strictly contingent upon the consummation of the Merger with Savara Inc. and the officer's continued service until that date.
- Option Cancellation Risk: The cancellation of outstanding stock options is contingent on the Merger; if the Merger does not close, these options remain outstanding (though likely underwater).
- Regulatory Filings: The Company intends to file a Form S-4 registration statement containing a joint proxy and information statement. Investors are urged to review these materials before making investment decisions.
- Lock-Up Restrictions: Shares from RSUs remain subject to lock-up restrictions, with the specific exception for tax withholding payments.
Investor Verification Checklist
- Verify the status of the Merger Agreement between Mast Therapeutics and Savara Inc. and the likelihood of consummation.
- Review the upcoming Form S-4 filing for details on the Exchange Ratio and the impact of the 16.4 million option cancellations.
- Confirm the specific vesting conditions and tax implications of the RSU grants for NEOs.
- Check the current market price of Mast Therapeutics stock relative to the $0.41 minimum exercise price of outstanding options to validate the "underwater" status mentioned in the filing.